Free Trial

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by Eagle Asset Management Inc.

Protagonist Therapeutics logo with Medical background

Eagle Asset Management Inc. decreased its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 17.7% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 294,280 shares of the company's stock after selling 63,353 shares during the period. Eagle Asset Management Inc. owned 0.50% of Protagonist Therapeutics worth $13,605,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Farallon Capital Management LLC raised its position in shares of Protagonist Therapeutics by 1.8% in the 2nd quarter. Farallon Capital Management LLC now owns 5,840,773 shares of the company's stock valued at $202,383,000 after purchasing an additional 101,800 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Protagonist Therapeutics by 1.2% in the first quarter. Vanguard Group Inc. now owns 3,192,971 shares of the company's stock worth $92,373,000 after buying an additional 39,055 shares during the last quarter. Pacer Advisors Inc. grew its holdings in shares of Protagonist Therapeutics by 405,061.2% during the third quarter. Pacer Advisors Inc. now owns 1,734,090 shares of the company's stock valued at $78,034,000 after buying an additional 1,733,662 shares during the last quarter. Perceptive Advisors LLC increased its position in shares of Protagonist Therapeutics by 27.6% in the 2nd quarter. Perceptive Advisors LLC now owns 1,268,735 shares of the company's stock valued at $43,962,000 after acquiring an additional 274,412 shares during the period. Finally, Millennium Management LLC raised its stake in Protagonist Therapeutics by 2,135.6% in the 2nd quarter. Millennium Management LLC now owns 958,283 shares of the company's stock worth $33,205,000 after acquiring an additional 915,418 shares during the last quarter. 98.63% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on PTGX. HC Wainwright reissued a "buy" rating and issued a $50.00 price objective on shares of Protagonist Therapeutics in a report on Tuesday, November 19th. Truist Financial assumed coverage on shares of Protagonist Therapeutics in a report on Monday, September 9th. They issued a "buy" rating and a $60.00 price objective on the stock. StockNews.com upgraded shares of Protagonist Therapeutics from a "hold" rating to a "buy" rating in a research report on Thursday, August 8th. TD Cowen upgraded Protagonist Therapeutics to a "strong-buy" rating in a research note on Wednesday, September 25th. Finally, Wedbush restated an "outperform" rating and issued a $58.00 target price on shares of Protagonist Therapeutics in a research note on Tuesday, November 19th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $53.57.

Read Our Latest Report on PTGX

Protagonist Therapeutics Stock Up 11.5 %

Shares of Protagonist Therapeutics stock traded up $4.81 on Friday, reaching $46.46. The company's stock had a trading volume of 1,322,201 shares, compared to its average volume of 733,287. Protagonist Therapeutics, Inc. has a 52-week low of $16.80 and a 52-week high of $48.89. The company has a market capitalization of $2.77 billion, a P/E ratio of 17.47 and a beta of 2.17. The stock has a 50-day moving average price of $45.25 and a 200-day moving average price of $39.26.

Insider Buying and Selling

In other news, Director William D. Waddill sold 8,000 shares of the company's stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $45.00, for a total transaction of $360,000.00. Following the completion of the sale, the director now owns 12,000 shares of the company's stock, valued at $540,000. This represents a 40.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Arturo Md Molina sold 1,906 shares of the firm's stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $40.98, for a total transaction of $78,107.88. Following the completion of the transaction, the insider now directly owns 46,444 shares in the company, valued at approximately $1,903,275.12. This represents a 3.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 24,109 shares of company stock worth $1,069,999 in the last 90 days. Insiders own 5.40% of the company's stock.

Protagonist Therapeutics Profile

(Free Report)

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.

Featured Stories

Institutional Ownership by Quarter for Protagonist Therapeutics (NASDAQ:PTGX)

Should you invest $1,000 in Protagonist Therapeutics right now?

Before you consider Protagonist Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Protagonist Therapeutics wasn't on the list.

While Protagonist Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

From Landfills to Profits: Opal Fuels CEO Shares How the Company Turns Trash into Cash
The Real Reason Tesla Stock Is Soaring – and Why Tech Expert Says It Won’t Stop
Best ETFs for 2025: Growth, Stability, and AI-Driven Investing

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines